Collagenase clostridium histolyticum intralesional injections for the treatment of Peyronie’s disease: a safety profile

Peyronie’s disease (PD) is a debilitating chronic condition associated with penile curvature, erectile dysfunction, pain, and emotional distress (1). The condition was first described in 1743 by Francois Gigot de la Peyronie, King Louis XV of France’s physician (2). PD is a progressive condition characterised by fibrotic plaques within the tunica albuginea which can lead to pain and penile curvature (2). Non-surgical and surgical management options exist, with surgery often being offered in the most severe cases (1,3). Surgery carries the potential morbidity of penile shortening, neurovascular injury and erectile dysfunction (3).